371 related articles for article (PubMed ID: 33558734)
1. Prolonged activation of innate immune pathways by a polyvalent STING agonist.
Li S; Luo M; Wang Z; Feng Q; Wilhelm J; Wang X; Li W; Wang J; Cholka A; Fu YX; Sumer BD; Yu H; Gao J
Nat Biomed Eng; 2021 May; 5(5):455-466. PubMed ID: 33558734
[TBL] [Abstract][Full Text] [Related]
2. Polyvalent design in the cGAS-STING pathway.
Bennett ZT; Li S; Sumer BD; Gao J
Semin Immunol; 2021 Aug; 56():101580. PubMed ID: 34920941
[TBL] [Abstract][Full Text] [Related]
3. TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN.
Temizoz B; Kuroda E; Ohata K; Jounai N; Ozasa K; Kobiyama K; Aoshi T; Ishii KJ
Eur J Immunol; 2015 Apr; 45(4):1159-69. PubMed ID: 25529558
[TBL] [Abstract][Full Text] [Related]
4. Zebularine elevates STING expression and enhances cGAMP cancer immunotherapy in mice.
Lai J; Fu Y; Tian S; Huang S; Luo X; Lin L; Zhang X; Wang H; Lin Z; Zhao H; Lin S; Zhao J; Xu S; Li D; Cai S; Dong L; Qian J; Liang J; Li Q; Zhang Y; Fan J; Balderas R; Chen Q
Mol Ther; 2021 May; 29(5):1758-1771. PubMed ID: 33571681
[TBL] [Abstract][Full Text] [Related]
5. A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer.
Cheng N; Watkins-Schulz R; Junkins RD; David CN; Johnson BM; Montgomery SA; Peine KJ; Darr DB; Yuan H; McKinnon KP; Liu Q; Miao L; Huang L; Bachelder EM; Ainslie KM; Ting JP
JCI Insight; 2018 Nov; 3(22):. PubMed ID: 30429378
[TBL] [Abstract][Full Text] [Related]
6. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
Demaria O; De Gassart A; Coso S; Gestermann N; Di Domizio J; Flatz L; Gaide O; Michielin O; Hwu P; Petrova TV; Martinon F; Modlin RL; Speiser DE; Gilliet M
Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15408-13. PubMed ID: 26607445
[TBL] [Abstract][Full Text] [Related]
7. Effective delivery of STING agonist using exosomes suppresses tumor growth and enhances antitumor immunity.
McAndrews KM; Che SPY; LeBleu VS; Kalluri R
J Biol Chem; 2021; 296():100523. PubMed ID: 33711340
[TBL] [Abstract][Full Text] [Related]
8. 2',3'-Cyclic GMP-AMP Dinucleotides for STING-Mediated Immune Modulation: Principles, Immunotherapeutic Potential, and Synthesis.
Shang M; Lu K; Guan W; Cao S; Ren M; Zhou C
ChemMedChem; 2022 Jan; 17(2):e202100671. PubMed ID: 34807508
[TBL] [Abstract][Full Text] [Related]
9. STING Agonist Mitigates Experimental Autoimmune Encephalomyelitis by Stimulating Type I IFN-Dependent and -Independent Immune-Regulatory Pathways.
Johnson BM; Uchimura T; Gallovic MD; Thamilarasan M; Chou WC; Gibson SA; Deng M; Tam JW; Batty CJ; Williams J; Matsushima GK; Bachelder EM; Ainslie KM; Markovic-Plese S; Ting JP
J Immunol; 2021 May; 206(9):2015-2028. PubMed ID: 33820855
[TBL] [Abstract][Full Text] [Related]
10. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.
Shae D; Becker KW; Christov P; Yun DS; Lytton-Jean AKR; Sevimli S; Ascano M; Kelley M; Johnson DB; Balko JM; Wilson JT
Nat Nanotechnol; 2019 Mar; 14(3):269-278. PubMed ID: 30664751
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral administration of cGAMP transiently accumulates potent macrophages for anti-tumor immunity at a mouse tumor site.
Ohkuri T; Kosaka A; Ishibashi K; Kumai T; Hirata Y; Ohara K; Nagato T; Oikawa K; Aoki N; Harabuchi Y; Celis E; Kobayashi H
Cancer Immunol Immunother; 2017 Jun; 66(6):705-716. PubMed ID: 28243692
[TBL] [Abstract][Full Text] [Related]
12. A critical role of STING-triggered tumor-migrating neutrophils for anti-tumor effect of intratumoral cGAMP treatment.
Nagata M; Kosaka A; Yajima Y; Yasuda S; Ohara M; Ohara K; Harabuchi S; Hayashi R; Funakoshi H; Ueda J; Kumai T; Nagato T; Oikawa K; Harabuchi Y; Esteban C; Ohkuri T; Kobayashi H
Cancer Immunol Immunother; 2021 Aug; 70(8):2301-2312. PubMed ID: 33507344
[TBL] [Abstract][Full Text] [Related]
13. Activation of STING by targeting a pocket in the transmembrane domain.
Lu D; Shang G; Li J; Lu Y; Bai XC; Zhang X
Nature; 2022 Apr; 604(7906):557-562. PubMed ID: 35388221
[TBL] [Abstract][Full Text] [Related]
14. STING activation in cancer immunotherapy.
Su T; Zhang Y; Valerie K; Wang XY; Lin S; Zhu G
Theranostics; 2019; 9(25):7759-7771. PubMed ID: 31695799
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis and Biological Evaluation of (2',5' and 3'5'-Linked) cGAMP Analogs that Activate Stimulator of Interferon Genes (STING).
Xie X; Liu J; Wang X
Molecules; 2020 Nov; 25(22):. PubMed ID: 33198423
[TBL] [Abstract][Full Text] [Related]
16. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
[TBL] [Abstract][Full Text] [Related]
17. STING agonists enable antiviral cross-talk between human cells and confer protection against genital herpes in mice.
Skouboe MK; Knudsen A; Reinert LS; Boularan C; Lioux T; Perouzel E; Thomsen MK; Paludan SR
PLoS Pathog; 2018 Apr; 14(4):e1006976. PubMed ID: 29608601
[TBL] [Abstract][Full Text] [Related]
18. Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response.
Li T; Cheng H; Yuan H; Xu Q; Shu C; Zhang Y; Xu P; Tan J; Rui Y; Li P; Tan X
Sci Rep; 2016 Jan; 6():19049. PubMed ID: 26754564
[TBL] [Abstract][Full Text] [Related]
19. STING agonist cGAMP enhances anti-tumor activity of CAR-NK cells against pancreatic cancer.
Da Y; Liu Y; Hu Y; Liu W; Ma J; Lu N; Zhang C; Zhang C
Oncoimmunology; 2022; 11(1):2054105. PubMed ID: 35371622
[TBL] [Abstract][Full Text] [Related]
20. Innate Immune Activation by cGMP-AMP Nanoparticles Leads to Potent and Long-Acting Antiretroviral Response against HIV-1.
Aroh C; Wang Z; Dobbs N; Luo M; Chen Z; Gao J; Yan N
J Immunol; 2017 Dec; 199(11):3840-3848. PubMed ID: 29084836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
